Sensei Biotherapeutics amends bylaws for universal proxy rules and DGCL updates

Sensei Biotherapeutics, Inc.

Enhanced disclosure requirements for stockholder nominations, including questionnaires and nominee resignation agreements.
Added provisions for Universal Proxy Rules (Rule 14a-19), requiring intent disclosure and evidence of compliance.
Clarified board authority to determine if nominations/proposals properly brought and to postpone/cancel meetings.
Updated provisions for remote meetings and adjournment procedures per recent DGCL amendments.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sensei Biotherapeutics, Inc.: Adopted amended and restated bylaws effective December 5, 2022, updating procedural mechanics, disclosures, universal proxy rules, and other conforming changes (effective 2022-12-05).

Change: bylaw amendment
Effective: 2022-12-05

Exact text from the filing

On December 5, 2022, in connection with the new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Sensei Biotherapeutics, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-301836

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.